Our portfolio
CEPI is working to end pandemics by supporting the research and development of a diverse portfolio of vaccine candidates based on a range of vaccine approaches.
Explore our portfolio
CEPI funds the development of vaccine candidates against our priority pathogens and vaccine platforms to enable rapid development of vaccines against Disease X. Our interactive portfolio provides information on each of the vaccine candidates that CEPI has invested in as well as our Centralised Lab Network and Vaccine Manufacturing Network partners. Additional CEPI-funded partnerships will be added in the coming months to provide a full overview of all of CEPI’s investments. Filter information by developer, disease, phase of development, or vaccine type. You can also download a summary of our active portfolio.
Portfolio: list view
20Meds
CEPI is providing US$850,000 for the development of 20Med's bioresponsive polymeric nanoparticle technology, which could help end the need for frozen storage of mRNA vaccines. This funding will be used to advance a proof-of-concept for 20Med's nanoparticle platform, as well as for preclinical studies to assess whether the technology can deliver mRNA vaccines as effectively as the currently approved technology used for mRNA delivery, known as lipid nanoparticles.
AVaxziPen
CEPI is providing up to US$1.6 million to establish proof-of-concept for aVaxziPen's vaccine-delivery technology by evaluating stability, delivery and preclinical immunogenicity of both mRNA and protein-based vaccines developed using aVaxziPen's platform.
aVaxziPen's solid-dose vaccine technology uses a pen applicator device and is designed to address access challenges associated with cold-chain storage requirements by protecting the mRNA and proteins against degradation, potentially removing the need for frozen storage for mRNA vaccines and the need for cold-chain storage altogether for protein-based vaccines.
Affinivax
CEPI supported the development of a vaccine candidate based on Affinivax’s innovative Multiple Antigen Presenting System (MAPSTM) technology.
The programme aimed to establish preclinical proof of concept for a vaccine candidate designed to protect against new COVID-19 variants suitable for use in the Global South.
CEPI funding has been discontinued.
Afrigen
CEPI is providing up to US$2.05 million to Afrigen Biologics to explore whether optimised synthetic DNA can help to reduce mRNA vaccine development timelines for emergency use in the event of a disease outbreak, in support of the 100 Days Mission.
Akagera Medicines
CEPI is providing up to US $1.5 million to Akagera Medicines to demonstrate the pre-clinical proof of concept of their lipid nanoparticles (LNPs) and modified mRNA for the development of a multivalent influenza vaccine.
Their LNP formulation could optimise delivery of mRNA and reduce potential LNP-associated adverse events.
The technology could also improve the stability of the mRNA-based vaccines, removing the need for frozen storage to bolster equitable vaccine access.
Benefits could also include enhanced shelf life, reduced Cost of Goods, and a reduction in the required effective dose which would extend the number of doses that could be produced.
